Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole versus tamoxifen safety study on bone mineral density and lipid profile in postmenopausal women with early breast cancer
2004-002418-12Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Letrozole arm with Tamoxifen arm (2 arms). Primary endpoint: Percent change from baseline in lumbar spine bone mineral density at 2 years. Started Jan 2005; status: completed.
02
Drugs
letrozoletamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-002418-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002418-12.